ConforMIS

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which it refers to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers.

BILLERICA, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will provide a business update and initial expectations for 2022 before the market opens on Thursday, January 6, 2022, at approximately 7:00 a.m. Eastern Time.

Conformis, Inc. to Provide Business Update and Initial Expectations for 2022 on January 6, 2022

BILLERICA, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Brent Alldredge, Chief Legal Officer and Corporate Secretary, has notified the Company that he will be departing the Company on January 16, 2022 to become the General Counsel at Bruker Corporation, a global, publicly traded developer, manufacturer, and distributor of scientific instruments and analytical and diagnostic solutions.

Conformis, Inc. Announces Departure of Chief Legal Officer, Corporate Secretary

BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing.

Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported

Conformis, Inc. (CFMS) CEO Mark Augusti on Q3 2021 Results - Earnings Call Transcript

ConforMIS (CFMS) delivered earnings and revenue surprises of 0.00% and 1.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q3 Loss, Tops Revenue Estimates

BILLERICA, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended September 30, 2021.

Conformis Reports Third Quarter 2021 Financial Results

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.

Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?

BILLERICA, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the third quarter ended September 30, 2021 after the market closes on November 3, 2021 at approximately 4:00 p.m. Eastern Time.

Conformis, Inc. to Release Third Quarter 2021 Financial Results on November 3, 2021

Conformis (CFMS) has been struggling lately, but the selling pressure may be coming to an end soon.

Conformis (CFMS) Sees Hammer Chart Pattern: Time to Buy?

Conformis Inc (NASDAQ: CFMS) announced results of a published retrospective study of procedures using Conformis' patient-specific iTotal CR (cruciate-retaining) knee replacement implant. Data showed that implant survivorship was 98.5% with 8 revisions (representing 1.5% of the 540 implants reviewed) at a mean follow-up of 2.8 years.

Conformis Posts Clinical Study Data For Its Knee Implants

A retrospective review of 540 procedures performed demonstrated 98.5% Implant Survivorship and 89.0% Patient Satisfaction for the Conformis patient-specific iTotal® CR (cruciate-retaining) knee replacement implants at mid-term follow-up A retrospective review of 540 procedures performed demonstrated 98.5% Implant Survivorship and 89.0% Patient Satisfaction for the Conformis patient-specific iTotal® CR (cruciate-retaining) knee replacement implants at mid-term follow-up

Conformis, Inc. Announces Strong Clinical Study Results for Its Personalized Knee Implants

Crocs

GreenSky

Range Resources

CROX, GSKY, RRC, and CFMS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 22, 2021

Top Ranked Momentum Stocks to Buy for September 22nd

A cut in revenue guidance didn't make investors happy.

Why Conformis Plummeted by Almost 11% on Wednesday

Conformis Inc (NASDAQ: CFMS) stock is down after the Q3 revenue update ahead of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.  Related Link:   Conformis Q2 Earnings Surpass Estimates On Higher Volumes And Royalties, License Revenue.

Investors React To Conformis' Annual Sales Guidance Update

Business Update Provided in Advance of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Business Update Provided in Advance of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Conformis, Inc. Provides Business Update

Aprea Therapeutics

Capricor Therapeutics

Spectrum Pharma

Verastem

Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts

Ampio Pharmaceuticals Inc

CASI Pharmaceuticals

Clovis Oncology

AB Corporate Bond ETF

Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks For Your Biotech Watch List In September 2021

BIOLASE

CBAK Energy Technology Inc

Hudson Technologies

Hive Blockchain Technologies Ltd

Sify Technologies Limited

TransGlobe Energy

As the global economy recovers in fits and starts, one way to play the long-term expansion in global markets is with solid penny stocks. The post 7 of the Best Penny Stocks for Any Portfolio appeared first on InvestorPlace.

7 of the Best Penny Stocks for Any Portfolio

Conformis is a small company developing knee and hip replacement implants. They have recent collaboration deals with major players.

Conformis: Emerging Surgical Implant Developer

BILLERICA, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) today announced the first procedure with the new Conformis Identity Imprint knee replacement system.

Conformis, Inc. Announces First Procedure Performed Using the Identity Imprint™ Knee Replacement System

Conformis Inc (NASDAQ: CFMS) Q2 revenues more than doubled to $56.3 million, beating the consensus of $33 million. The increase was driven primarily by elective procedure volumes and royalty & licensing revenue related to patent license settlement and development agreements.

Conformis Q2 Earnings Surpass Estimates On Higher Volumes And Royalties, License Revenue

Conformis, Inc. (CFMS) CEO Mark Augusti on Q2 2021 Results - Earnings Call Transcript

ConforMIS (CFMS) delivered earnings and revenue surprises of 162.50% and 43.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Surpasses Q2 Earnings and Revenue Estimates

Color Star Technology

Dare Bioscience

Which Penny Stocks Are Investors Watching As August Gets Off to a Strong Start? The post Top Penny Stocks to Watch to Start Your Week Off Right  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for ConforMIS Stock (CFMS)